{"id":"https://openalex.org/W1978586089","doi":"https://doi.org/10.1007/s13300-013-0045-8","title":"Dipeptidyl Peptidase-4 Inhibition in Patients with Type 2 Diabetes Treated with Saxagliptin, Sitagliptin, or Vildagliptin","display_name":"Dipeptidyl Peptidase-4 Inhibition in Patients with Type 2 Diabetes Treated with Saxagliptin, Sitagliptin, or Vildagliptin","publication_year":2013,"publication_date":"2013-10-25","ids":{"openalex":"https://openalex.org/W1978586089","doi":"https://doi.org/10.1007/s13300-013-0045-8","mag":"1978586089","pmid":"https://pubmed.ncbi.nlm.nih.gov/24163113","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/3889317"},"language":"en","primary_location":{"id":"doi:10.1007/s13300-013-0045-8","doi":"https://doi.org/10.1007/s13300-013-0045-8","is_oa":true,"landing_page_url":"https://doi.org/10.1007/s13300-013-0045-8","pdf_url":"https://link.springer.com/content/pdf/10.1007/s13300-013-0045-8.pdf","source":{"id":"https://openalex.org/S16535137","display_name":"Diabetes Therapy","issn_l":"1869-6953","issn":["1869-6953","1869-6961"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-d","doyens","jufo-1","ki-jl-1","norway-1","oarl","poland-100","russia-white-list-2"],"host_organization":"https://openalex.org/P4310320330","host_organization_name":"Adis, Springer Healthcare","host_organization_lineage":["https://openalex.org/P4310320330","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Adis, Springer Healthcare","Springer Nature"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Diabetes Therapy","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","doaj","pubmed"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://link.springer.com/content/pdf/10.1007/s13300-013-0045-8.pdf","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5013234560","display_name":"Daniel A. Tatosian","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1285764155","display_name":"Merck & Co., Inc., Rahway, NJ, USA (United States)","ror":"https://ror.org/02891sr49","country_code":"US","type":"company","lineage":["https://openalex.org/I1285764155"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Daniel A. Tatosian","raw_affiliation_strings":["Merck & Co., Inc., One Merck Drive, P.O. Box 100, Whitehouse Station, NJ, 08889-0100, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Merck & Co., Inc., One Merck Drive, P.O. Box 100, Whitehouse Station, NJ, 08889-0100, USA","institution_ids":["https://openalex.org/I1285764155"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100633193","display_name":"Ying Qing Guo","orcid":"https://orcid.org/0000-0002-5729-2986","observed_orcids":["https://orcid.org/0000-0002-5729-2986"]},"institutions":[{"id":"https://openalex.org/I1285764155","display_name":"Merck & Co., Inc., Rahway, NJ, USA (United States)","ror":"https://ror.org/02891sr49","country_code":"US","type":"company","lineage":["https://openalex.org/I1285764155"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ying Guo","raw_affiliation_strings":["Merck & Co., Inc., One Merck Drive, P.O. Box 100, Whitehouse Station, NJ, 08889-0100, USA","Merck & Co. Inc., Whitehouse Station, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Merck & Co., Inc., One Merck Drive, P.O. Box 100, Whitehouse Station, NJ, 08889-0100, USA","institution_ids":["https://openalex.org/I1285764155"]},{"raw_affiliation_string":"Merck & Co. Inc., Whitehouse Station, USA","institution_ids":["https://openalex.org/I1285764155"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5072995863","display_name":"Andrea K. Schaeffer","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1285764155","display_name":"Merck & Co., Inc., Rahway, NJ, USA (United States)","ror":"https://ror.org/02891sr49","country_code":"US","type":"company","lineage":["https://openalex.org/I1285764155"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Andrea K. Schaeffer","raw_affiliation_strings":["Merck & Co., Inc., One Merck Drive, P.O. Box 100, Whitehouse Station, NJ, 08889-0100, USA","Merck & Co. Inc., Whitehouse Station, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Merck & Co., Inc., One Merck Drive, P.O. Box 100, Whitehouse Station, NJ, 08889-0100, USA","institution_ids":["https://openalex.org/I1285764155"]},{"raw_affiliation_string":"Merck & Co. Inc., Whitehouse Station, USA","institution_ids":["https://openalex.org/I1285764155"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5009707371","display_name":"Natalia Gaibu","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Natalia Gaibu","raw_affiliation_strings":["ARENSIA Exploratory Medicine, Republican Clinical Hospital, N. Testemitanu str, nr 29, Chi\u015fin\u0103u, Republic of Moldova","ARENSIA Exploratory Medicine, Republican Clinical Hospital, Chi\u015fin\u0103u, Republic of Moldova"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"ARENSIA Exploratory Medicine, Republican Clinical Hospital, N. Testemitanu str, nr 29, Chi\u015fin\u0103u, Republic of Moldova","institution_ids":[]},{"raw_affiliation_string":"ARENSIA Exploratory Medicine, Republican Clinical Hospital, Chi\u015fin\u0103u, Republic of Moldova","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5060272056","display_name":"Serghei Popa","orcid":"https://orcid.org/0000-0001-9348-4187","observed_orcids":["https://orcid.org/0000-0001-9348-4187"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Serghei Popa","raw_affiliation_strings":["ARENSIA Exploratory Medicine, Republican Clinical Hospital, N. Testemitanu str, nr 29, Chi\u015fin\u0103u, Republic of Moldova","ARENSIA Exploratory Medicine, Republican Clinical Hospital, Chi\u015fin\u0103u, Republic of Moldova"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"ARENSIA Exploratory Medicine, Republican Clinical Hospital, N. Testemitanu str, nr 29, Chi\u015fin\u0103u, Republic of Moldova","institution_ids":[]},{"raw_affiliation_string":"ARENSIA Exploratory Medicine, Republican Clinical Hospital, Chi\u015fin\u0103u, Republic of Moldova","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5108214003","display_name":"Aubrey Stoch","orcid":"https://orcid.org/0000-0001-5620-7092","observed_orcids":["https://orcid.org/0000-0001-5620-7092"]},"institutions":[{"id":"https://openalex.org/I1285764155","display_name":"Merck & Co., Inc., Rahway, NJ, USA (United States)","ror":"https://ror.org/02891sr49","country_code":"US","type":"company","lineage":["https://openalex.org/I1285764155"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Aubrey Stoch","raw_affiliation_strings":["Merck & Co., Inc., One Merck Drive, P.O. Box 100, Whitehouse Station, NJ, 08889-0100, USA","Merck & Co. Inc., Whitehouse Station, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Merck & Co., Inc., One Merck Drive, P.O. Box 100, Whitehouse Station, NJ, 08889-0100, USA","institution_ids":["https://openalex.org/I1285764155"]},{"raw_affiliation_string":"Merck & Co. Inc., Whitehouse Station, USA","institution_ids":["https://openalex.org/I1285764155"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5002660940","display_name":"Ronald B. Langdon","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1285764155","display_name":"Merck & Co., Inc., Rahway, NJ, USA (United States)","ror":"https://ror.org/02891sr49","country_code":"US","type":"company","lineage":["https://openalex.org/I1285764155"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ronald B. Langdon","raw_affiliation_strings":["Merck & Co., Inc., One Merck Drive, P.O. Box 100, Whitehouse Station, NJ, 08889-0100, USA","Merck & Co. Inc., Whitehouse Station, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Merck & Co., Inc., One Merck Drive, P.O. Box 100, Whitehouse Station, NJ, 08889-0100, USA","institution_ids":["https://openalex.org/I1285764155"]},{"raw_affiliation_string":"Merck & Co. Inc., Whitehouse Station, USA","institution_ids":["https://openalex.org/I1285764155"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5029797983","display_name":"Eunkyung A. Kauh","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1285764155","display_name":"Merck & Co., Inc., Rahway, NJ, USA (United States)","ror":"https://ror.org/02891sr49","country_code":"US","type":"company","lineage":["https://openalex.org/I1285764155"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Eunkyung A. Kauh","raw_affiliation_strings":["Merck & Co., Inc., One Merck Drive, P.O. Box 100, Whitehouse Station, NJ, 08889-0100, USA","Merck & Co. Inc., Whitehouse Station, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Merck & Co., Inc., One Merck Drive, P.O. Box 100, Whitehouse Station, NJ, 08889-0100, USA","institution_ids":["https://openalex.org/I1285764155"]},{"raw_affiliation_string":"Merck & Co. Inc., Whitehouse Station, USA","institution_ids":["https://openalex.org/I1285764155"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5029797983"],"corresponding_institution_ids":["https://openalex.org/I1285764155"],"apc_list":{"value":7400,"currency":"USD","value_usd":7400},"apc_paid":{"value":7400,"currency":"USD","value_usd":7400},"fwci":2.8517,"has_fulltext":true,"cited_by_count":48,"citation_normalized_percentile":{"value":0.90491529,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":88,"max":99},"biblio":{"volume":"4","issue":"2","first_page":"431","last_page":"442"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12505","display_name":"Peptidase Inhibition and Analysis","score":0.0003000000142492354,"subfield":{"id":"https://openalex.org/subfields/1303","display_name":"Biochemistry"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10560","display_name":"Diabetes Management and Research","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/dpp-4-inhibitors","display_name":"DPP-4 inhibitors","score":0.9279999732971191},{"id":"https://openalex.org/keywords/saxagliptin","display_name":"saxagliptin","score":0.9430000185966492},{"id":"https://openalex.org/keywords/sitagliptin","display_name":"sitagliptin","score":1.0},{"id":"https://openalex.org/keywords/vildagliptin","display_name":"vildagliptin","score":1.0},{"id":"https://openalex.org/keywords/type-2-diabetes","display_name":"type 2 diabetes","score":0.9089999794960022},{"id":"https://openalex.org/keywords/dpp-4-inhibition","display_name":"DPP-4 inhibition","score":0.9449999928474426},{"id":"https://openalex.org/keywords/trough-concentration","display_name":"trough concentration","score":0.6679999828338623},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.625},{"id":"https://openalex.org/keywords/hba1c","display_name":"HbA1c","score":0.5889999866485596},{"id":"https://openalex.org/keywords/antidiabetic-drugs","display_name":"antidiabetic drugs","score":0.7319999933242798},{"id":"https://openalex.org/keywords/drug-comparison","display_name":"drug comparison","score":0.3930000066757202},{"id":"https://openalex.org/keywords/dose-comparison","display_name":"dose comparison","score":0.49300000071525574},{"id":"https://openalex.org/keywords/crossover-design","display_name":"crossover design","score":0.3700000047683716},{"id":"https://openalex.org/keywords/hba1c-reduction","display_name":"HbA1c reduction","score":0.5989999771118164},{"id":"https://openalex.org/keywords/glycemic-control","display_name":"glycemic control","score":0.4350000023841858}],"concepts":[{"id":"https://openalex.org/C2780282729","wikidata":"https://www.wikidata.org/wiki/Q3121121","display_name":"Saxagliptin","level":5,"score":0.9886052012443542},{"id":"https://openalex.org/C2776453732","wikidata":"https://www.wikidata.org/wiki/Q421042","display_name":"Vildagliptin","level":4,"score":0.9836835265159607},{"id":"https://openalex.org/C2779284873","wikidata":"https://www.wikidata.org/wiki/Q419832","display_name":"Sitagliptin","level":4,"score":0.9556145668029785},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8591129779815674},{"id":"https://openalex.org/C2778763485","wikidata":"https://www.wikidata.org/wiki/Q419770","display_name":"Dipeptidyl peptidase-4 inhibitor","level":4,"score":0.6647279858589172},{"id":"https://openalex.org/C2777180221","wikidata":"https://www.wikidata.org/wiki/Q3025883","display_name":"Type 2 diabetes","level":3,"score":0.6217918992042542},{"id":"https://openalex.org/C156490143","wikidata":"https://www.wikidata.org/wiki/Q412214","display_name":"Dipeptidyl peptidase-4","level":4,"score":0.6117963194847107},{"id":"https://openalex.org/C555293320","wikidata":"https://www.wikidata.org/wiki/Q12206","display_name":"Diabetes mellitus","level":2,"score":0.5792858004570007},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.4517298936843872},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.43191924691200256},{"id":"https://openalex.org/C2781469919","wikidata":"https://www.wikidata.org/wiki/Q5279728","display_name":"Dipeptidyl peptidase","level":3,"score":0.42601561546325684},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.40813255310058594},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.1595974564552307},{"id":"https://openalex.org/C181199279","wikidata":"https://www.wikidata.org/wiki/Q8047","display_name":"Enzyme","level":2,"score":0.12773174047470093},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.06863704323768616}],"mesh":[],"locations_count":5,"locations":[{"id":"doi:10.1007/s13300-013-0045-8","doi":"https://doi.org/10.1007/s13300-013-0045-8","is_oa":true,"landing_page_url":"https://doi.org/10.1007/s13300-013-0045-8","pdf_url":"https://link.springer.com/content/pdf/10.1007/s13300-013-0045-8.pdf","source":{"id":"https://openalex.org/S16535137","display_name":"Diabetes Therapy","issn_l":"1869-6953","issn":["1869-6953","1869-6961"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-d","doyens","jufo-1","ki-jl-1","norway-1","oarl","poland-100","russia-white-list-2"],"host_organization":"https://openalex.org/P4310320330","host_organization_name":"Adis, Springer Healthcare","host_organization_lineage":["https://openalex.org/P4310320330","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Adis, Springer Healthcare","Springer Nature"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Diabetes Therapy","raw_type":"journal-article"},{"id":"pmh:oai:europepmc.org:2876908","doi":null,"is_oa":true,"landing_page_url":"http://europepmc.org/articles/PMC3889317","pdf_url":null,"source":{"id":"https://openalex.org/S4306400806","display_name":"Europe PMC (PubMed Central)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1303153112","host_organization_name":"European Bioinformatics Institute","host_organization_lineage":["https://openalex.org/I1303153112"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"","raw_type":"Text"},{"id":"pmh:oai:pubmedcentral.nih.gov:3889317","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/3889317","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Diabetes Ther","raw_type":"Text"},{"id":"pmid:24163113","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/24163113","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Diabetes therapy : research, treatment and education of diabetes and related disorders","raw_type":"Journal Article"},{"id":"pmh:oai:CiteSeerX.psu:10.1.1.1033.3194","doi":null,"is_oa":false,"landing_page_url":"http://citeseerx.ist.psu.edu/viewdoc/summary?doi=10.1.1.1033.3194","pdf_url":null,"source":null,"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"http://europepmc.org/backend/ptpmcrender.fcgi?accid%3DPMC3889317%26blobtype%3Dpdf","raw_type":"text"}],"best_oa_location":{"id":"doi:10.1007/s13300-013-0045-8","doi":"https://doi.org/10.1007/s13300-013-0045-8","is_oa":true,"landing_page_url":"https://doi.org/10.1007/s13300-013-0045-8","pdf_url":"https://link.springer.com/content/pdf/10.1007/s13300-013-0045-8.pdf","source":{"id":"https://openalex.org/S16535137","display_name":"Diabetes Therapy","issn_l":"1869-6953","issn":["1869-6953","1869-6961"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-d","doyens","jufo-1","ki-jl-1","norway-1","oarl","poland-100","russia-white-list-2"],"host_organization":"https://openalex.org/P4310320330","host_organization_name":"Adis, Springer Healthcare","host_organization_lineage":["https://openalex.org/P4310320330","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Adis, Springer Healthcare","Springer Nature"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Diabetes Therapy","raw_type":"journal-article"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":1.0}],"study_designs":[{"id":"https://openalex.org/study-designs/randomized-controlled-trial","display_name":"Randomized Controlled Trial"},{"id":"https://openalex.org/study-designs/clinical-trial","display_name":"Clinical Trial"}],"awards":[],"funders":[],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W1978586089.pdf","grobid_xml":"https://content.openalex.org/works/W1978586089.grobid-xml"},"referenced_works_count":22,"referenced_works":["https://openalex.org/W1981747359","https://openalex.org/W1984635769","https://openalex.org/W1998673520","https://openalex.org/W2012235474","https://openalex.org/W2038445107","https://openalex.org/W2054185381","https://openalex.org/W2064410761","https://openalex.org/W2072402715","https://openalex.org/W2076262844","https://openalex.org/W2078126254","https://openalex.org/W2103870770","https://openalex.org/W2104025164","https://openalex.org/W2109688740","https://openalex.org/W2112852213","https://openalex.org/W2114927834","https://openalex.org/W2118609667","https://openalex.org/W2134760433","https://openalex.org/W2141264129","https://openalex.org/W2150859826","https://openalex.org/W2161075296","https://openalex.org/W4233939878","https://openalex.org/W4285719527"],"related_works":["https://openalex.org/W7096749690","https://openalex.org/W1985523042","https://openalex.org/W2377087575","https://openalex.org/W2320901530","https://openalex.org/W1987918436","https://openalex.org/W1916480346","https://openalex.org/W2918770834","https://openalex.org/W2797646286","https://openalex.org/W2912355198","https://openalex.org/W4397037895"],"abstract_inverted_index":{"INTRODUCTION:":[0],"Saxagliptin,":[1],"sitagliptin,":[2],"and":[3,84,90,149,161,185,192,232,276,301],"vildagliptin":[4,110,115,297,307],"are":[5],"dipeptidyl":[6],"peptidase-4":[7],"(DPP-4)":[8],"inhibitors":[9],"widely":[10],"approved":[11],"for":[12,72,120,159],"use":[13],"in":[14,37,145,203,264,280],"patients":[15,42,58,96,196],"with":[16,43,142,156,198,211,219,227,236,286],"type":[17,44],"2":[18,45],"diabetes.":[19,46],"Using":[20],"a":[21,38,50,152],"crossover":[22,55],"design,":[23],"the":[24,81,138,146,200,272],"present":[25],"study":[26,94,273],"compared":[27],"trough":[28,127,177,204,260,289],"levels":[29],"of":[30,41,62,252,266],"DPP-4":[31,133,290],"inhibition":[32,179,206,243,291],"provided":[33,288,305],"by":[34,131,306],"these":[35,256],"agents":[36],"single":[39],"cohort":[40],"METHODS:":[47],"This":[48],"was":[49,126,168,180,207,244],"randomized,":[51],"placebo-controlled,":[52],"open-label,":[53],"five-period":[54],"study.":[56],"Eligible":[57],"were":[59,274],"18-65":[60],"years":[61],"age,":[63],"either":[64],"treatment-na\u00efve":[65],"or":[66,76,118,278,296],"off":[67],"prior":[68,82],"antihyperglycemic":[69],"agent":[70],"therapy":[71],"at":[73,247,259],"least":[74],"6":[75],"12":[77,248],"weeks":[78],"(depending":[79],"on":[80],"therapy),":[83],"had":[85],"glycated":[86],"hemoglobin":[87],"(HbA1C)":[88],"\u22656.5%":[89],"\u226410.0%.":[91],"In":[92,195],"separate":[93],"periods,":[95],"received":[97],"5":[98,121],"mg":[99,104,109,114],"saxagliptin":[100,295],"q.d.":[101,106,111],"(saxa-5),":[102],"100":[103],"sitagliptin":[105,287],"(sita-100),":[107],"50":[108,113],"(vilda-50-q.d.),":[112],"b.i.d.":[116],"(vilda-50-b.i.d.),":[117],"placebo":[119,237],"days.":[122],"The":[123],"primary":[124],"endpoint":[125],"%DPP-4":[128,178,205,242],"inhibition,":[129],"derived":[130],"comparing":[132],"activity":[134,144],"24":[135],"h":[136,249],"after":[137,187],"Day-5":[139],"morning":[140],"dose":[141],"predose":[143],"same":[147],"period":[148],"analyzed":[150],"using":[151],"linear":[153],"mixed-effects":[154],"model":[155],"fixed-effects":[157],"terms":[158],"treatment":[160,285],"period.":[162],"RESULTS:":[163],"Mean":[164,241],"(range)":[165],"baseline":[166],"HbA1C":[167],"7.4%":[169],"(6.4-9.0%;":[170],"N":[171],"=":[172,230],"22).":[173],"Least-squares":[174],"(LS)":[175],"mean":[176],"73.5%,":[181],"91.7%,":[182],"28.9%,":[183],"90.6%,":[184],"3.5%":[186],"saxa-5,":[188],"sita-100,":[189,199],"vilda-50-q.d.,":[190],"vilda-50-b.i.d.,":[191],"placebo,":[193],"respectively.":[194],"treated":[197],"LS-mean":[201],"difference":[202],"18.2%":[208],"greater":[209,217,225,234,293],"than":[210,218,226,235,294],"saxa-5":[212],"(p":[213,221,229,238],"<":[214,222,239],"0.001),":[215,223],"62.9%":[216],"vilda-50-q.d.":[220],"1.1%":[224],"vilda-50-b.i.d.":[228],"0.128),":[231],"87.8%":[233],"0.001).":[240],"nearly":[245],"maximal":[246],"postdose":[250],"regardless":[251],"active":[253],"treatment.":[254],"Thus,":[255],"between-group":[257],"comparisons":[258],"primarily":[261],"reflected":[262],"differences":[263],"duration":[265],"action.":[267],"Adverse":[268],"events":[269],"reported":[270],"during":[271],"transient":[275],"mild":[277],"moderate":[279],"intensity.":[281],"CONCLUSION:":[282],"Once":[283],"daily":[284],"significantly":[292],"administered":[298,308],"once":[299],"daily,":[300],"similar":[302],"to":[303],"that":[304],"twice":[309],"daily.":[310]},"counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2025,"cited_by_count":2},{"year":2023,"cited_by_count":1},{"year":2022,"cited_by_count":2},{"year":2021,"cited_by_count":4},{"year":2020,"cited_by_count":5},{"year":2019,"cited_by_count":11},{"year":2018,"cited_by_count":2},{"year":2017,"cited_by_count":6},{"year":2016,"cited_by_count":5},{"year":2015,"cited_by_count":5},{"year":2014,"cited_by_count":4}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2016-06-24T00:00:00"}